MYUNG IN PHARMA CO LTD (317450.KS) stock: key figures, P/E, revenue and dividend

Health Care · South Korea

Price
39,600.00 KRW
Market cap
578.16 bn KRW
P/E (2025)
7.10
P/S (2025)
2.01
Dividend yield
5.05 %
Net margin
28.35 %
Return on equity (ROE)
10.25 %
Return on assets (ROA)
9.68 %

MYUNG IN PHARMA CO LTD financials

Fiscal year2025
Revenue287.25 bn KRW
Gross profit173.99 bn KRW
Operating income92.50 bn KRW
EBIT102.35 bn KRW
Net income81.44 bn KRW
Diluted EPS – continuing operations5,577.75 KRW

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About MYUNG IN PHARMA CO LTD

Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate, haloperidol, paroxetine hcl, pimozide, quetiapine fumarate, rasagiline mesylate, risperidone, sumatriptan succinate, trazodone hci, triazolam, levetiracetam, carbamazepine, benserazide hydrochloride, escitalopram oxalate, vortioxetine hbr, brivaracetam, edoxban tosylate, opicapone, brexpiprazole, guanfacine hydrochloride, lacosamide, lurasidone hydrochloride. Myung In Pharmaceutical LTD. was founded in 1985 and is based in Hwaseong-si, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.